Advances in Immune Therapies for Hematological Malignancies
A Special Issue of Cancers (ISSN 2072-6694) belonging to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 258
Editor
Interests: basic and cellular immunology; cellular and cytokines immunotherapies; allo/auto HSCT; GvHD; viral infection; autoimmune diseases; clinical research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematological malignancies, including leukemia, lymphoma, and multiple myeloma, remain a major cause of morbidity and mortality worldwide. While conventional chemotherapy and hematopoietic stem cell transplantation have improved outcomes for many patients, their use is often limited by treatment-related toxicities, disease relapse, and complications such as graft-versus-host disease (GVHD) and opportunistic infections. These challenges continue to drive the development of more targeted and better-tolerated therapeutic strategies.
Immunotherapy has become an integral component in the management of hematological malignancies, supported by advances in understanding tumor–immune interactions and mechanisms of immune escape. Clinically established approaches include monoclonal antibodies, immune checkpoint inhibitors, and chimeric antigen receptor (CAR) T-cell therapies. In addition, bispecific monoclonal antibodies (Bi MoAbs) have recently emerged as a promising and rapidly evolving class of immunotherapies, offering novel mechanisms to redirect immune effector cells toward malignant targets. Other immune-modulating strategies are also under active investigation. In parallel, optimizing immune reconstitution following allogeneic or autologous transplantation, as well as managing infection risks such as cytomegalovirus (CMV), remain important areas of research.
This Special Issue will focus on recent progress in immune-based therapies for hematological malignancies, with particular emphasis on emerging approaches such as bispecific antibodies, alongside allo/auto BMT, GVHD, and other immunotherapeutic strategies. Original articles and comprehensive reviews spanning basic, translational, and clinical research are welcome.
Dr. Mohammad S. Hossain
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematological malignancies
- immunotherapy
- bone marrow transplantation
- graft-versus-host disease (GVHD)
- CAR T-cell therapy
- immune checkpoint inhibitors
- bispecific monoclonal antibodies
- cytomegalovirus (CMV) infection
- antigen–antibody interactions
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
